{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:49:50Z","timestamp":1760986190766,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.leukres.2023.107075","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:17:30Z","timestamp":1680747450000},"page":"107075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-7970","authenticated-orcid":false,"given":"Lindsay","family":"Wilde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-7482","authenticated-orcid":false,"given":"Patrizia","family":"Porazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"De Dominici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Palmisiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Keiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin","family":"Rancani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Yingling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Calabretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8616-744X","authenticated-orcid":false,"given":"Margaret","family":"Kasner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Epidemiology, and End Results SEER*Stat Database: Cancer Stat Facts: Leukemia \u2014 Acute Lymphocytic Leukemia (ALL)","author":"National Program of Cancer Registries and Surveillance","key":"10.1016\/j.leukres.2023.107075_bib1"},{"key":"10.1016\/j.leukres.2023.107075_bib2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107075_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bmt.2008.1","article-title":"Allogeneic transplantation for ALL in adults","volume":"41","author":"Stein","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2023.107075_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2012.225","article-title":"Role and potential for therapeutic targeting of MYB in leukemia","volume":"27","author":"Pattabiraman","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107075_bib5","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1073\/pnas.88.6.2351","article-title":"Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging","volume":"88","author":"Calabretta","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2023.107075_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ajh.23283","article-title":"Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis","volume":"87","author":"Sarvaiya","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107075_bib7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-17-2644","article-title":"Targeting CDK6 and BCL2 exploits the \u201cMYB addiction\u201d of Ph+ acute lymphoblastic leukemia","volume":"78","author":"De Dominici","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2023.107075_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mce.2012.03.024","article-title":"c-Myb interacts with the glucocorticoid receptor and regulates its level in pre-B-acute lymphoblastic leukemia cells","volume":"361","author":"Sarvaiya","year":"2012","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.leukres.2023.107075_bib9","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107075_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","article-title":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","volume":"107","author":"Bride","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107075_bib11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2023.107075_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-141572","article-title":"Safety of palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a children's oncology group pilot study","volume":"136","author":"Raetz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107075_bib13","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1182\/blood-2018-99-117334","article-title":"Phase I study of palbociclib alone and in combination in patients with relapsed and refractory (R\/R) leukemias","volume":"132","author":"Kadia","year":"2018","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:05Z","timestamp":1758935045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":13,"alternative-id":["S0145212623000607"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107075","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107075"}}